J&J CEO says curing certain cancers within a decade is realistic

Duato made the remarks connected Wednesday astatine the WSJ Leadership Institute CEO Summit successful London. Eradicating crab wholly and helping radical unrecorded longer, healthier lives represents the company's eventual goal, Duato added.

Reaching the apical spot successful oncology by 2030 is among J&J's stated targets, with deals successful the pipeline expected to bring caller crab attraction platforms into the company's portfolio implicit the adjacent respective years, according to the Journal. On the exertion front, Duato said AI has begun accelerating J&J's cause improvement process, though however overmuch fiscal payment the institution volition yet recognize from it remains unclear.

The comments came 2 days aft J&J agreed to get Firefly Bio, Inc. for $1 cardinal successful cash, expanding its crab cause pipeline with a level designed to dainty tumors that person resisted accepted therapies. At the halfway of the woody is Firefly's Firelink platform, which is designed to present protein-degrading drugs wrong crab cells by attaching them to antibodies — a strategy intended to trim the harm to steadfast insubstantial associated with existing treatments. The level targets tumors driven by a mutation successful a cistron known arsenic KRAS, the institution said.

"KRAS has notoriously been considered an undruggable people and patients with KRAS-driven cancers proceed to look constricted attraction options with endurance measured successful months, not years," John Reed, enforcement vice president of innovative medicine, probe and improvement astatine Johnson & Johnson, said successful a statement. "We judge the proprietary Firelink level volition flooded the limitations of existent treatments and diversify our pipeline with preclinical candidates for treating aggregate types of coagulated tumors."

J&J expects the Firefly Bio woody to adjacent earlier the extremity of 2026, pending regulatory approvals and different modular closing conditions, the institution said. The acquisition builds connected a play of wide momentum successful J&J's oncology business. The institution reported first-quarter gross of $24.1 billion, up astir 10% from a twelvemonth earlier, and raised its full-year 2026 income outlook to a scope of $100.3 cardinal to $101.3 billion. J&J besides committed much than $1 cardinal during the 4th to physique a compartment therapy manufacturing installation successful Pennsylvania.